US › Healthcare

Cadrenal Therapeutics, Inc. Common Stock (CVKD)

US · Healthcare · Biotechnology

$1.12+3.70%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.3M

EPS

$-1.14

EPS estimate

$-1.16

EPS came in at -1.14 against a street estimate of -1.16 — a beat of 1.7%.

Key statistics

Market cap

$3.9M

Forward P/E

0.0

P/B

0.95

Book value

$1.32

EPS (TTM)

$-4.88

52-week high

$14.64

52-week low

$1.00

50-day MA

$1.97

200-day MA

$5.28

Beta

1.84

Analyst view

Analysts rate Cadrenal Therapeutics, Inc. Common Stock a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $14.00.

Shareholding

Insiders

11.93%

Institutions

9.75%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	1.27%
Geode Capital Management, LLC	0.61%
Vanguard Fiduciary Trust Co	0.23%
JPMorgan Chase & Co	0.21%
BlackRock Inc	0.15%
Cygnus Capital Advisors, LLC	0.04%
Coconut Grove Bank	0.03%
Tower Research Capital LLC	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cadrenal Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.